The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. 1985

K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg

Studies performed on 18 patients with Parkinson's disease and 6 control subjects have shown that acute administration of L-DOPA in clinically effective doses gives rise to a diffuse increase in regional cerebral blood flow without accompanying stimulation of regional oxygen utilization. The data suggest that this rise in rCBF is caused by vasodilatation due to a direct action of the drug on the cerebral blood vessels. The effect of L-DOPA on rCBF did not correlate with the degree of clinical improvement seen in each patient after treatment. The therapeutic effect of L-DOPA in the brain was not reflected in any change of regional cerebral oxygen utilization as measured by our technique. We suggest that the pharmacological actions of L-DOPA in the brain take place on at least two different levels.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D002560 Cerebrovascular Circulation The circulation of blood through the BLOOD VESSELS of the BRAIN. Brain Blood Flow,Regional Cerebral Blood Flow,Cerebral Blood Flow,Cerebral Circulation,Cerebral Perfusion Pressure,Circulation, Cerebrovascular,Blood Flow, Brain,Blood Flow, Cerebral,Brain Blood Flows,Cerebral Blood Flows,Cerebral Circulations,Cerebral Perfusion Pressures,Circulation, Cerebral,Flow, Brain Blood,Flow, Cerebral Blood,Perfusion Pressure, Cerebral,Pressure, Cerebral Perfusion
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
October 1988, No to shinkei = Brain and nerve,
K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
November 1994, Rinsho shinkeigaku = Clinical neurology,
K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
August 1999, Journal of the neurological sciences,
K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
May 2012, NeuroImage,
K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
June 1979, Archives of neurology,
K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
March 1996, The International journal of neuroscience,
K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
January 1988, Journal of the neurological sciences,
K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
June 2017, Experimental neurology,
K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
April 1983, Nihon Ika Daigaku zasshi,
K L Leenders, and L Wolfson, and J M Gibbs, and R J Wise, and R Causon, and T Jones, and N J Legg
August 1992, Rinsho shinkeigaku = Clinical neurology,
Copied contents to your clipboard!